Can a drug delay diabetes? new study follows teplizumab patients for years
NCT ID NCT07360080
First seen Jan 26, 2026 · Last updated May 21, 2026 · Updated 18 times
Summary
This study follows 1,000 people with early-stage (Stage 2) Type 1 Diabetes who received teplizumab during routine care. Researchers want to see how long the drug delays progression to full-blown (Stage 3) diabetes and how it affects quality of life. Participants are observed for up to several years, and the study collects real-world data on side effects and long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Investigational Site Number: 3760001
RECRUITINGRamat Gan, 5265601, Israel
-
Investigational Site Number: 8400005
RECRUITINGSandy City, Utah, 84093, United States
Conditions
Explore the condition pages connected to this study.